Literature DB >> 18500639

Galanin and epilepsy.

J T Lerner1, R Sankar, A M Mazarati.   

Abstract

Neuroanatomical localization and physiological properties of galanin suggest that the peptide may be involved in the regulation of seizures. Indeed, administration of galanin receptor agonists into brain areas pertinent to the initiation and propagation of epileptic activity attenuated seizure responses under conditions of animal models of epilepsy; pharmacological blocking of galanin receptors exerted proconvulsant effects. Functional deletion of both galanin and galanin type 1 receptor genes produced transgenic mice with either spontaneous seizure phenotype, or with enhanced susceptibility to seizure stimuli. At the same time, overexpression of galanin in seizure pathways, using both transgenic and virus vector transfection techniques, hindered the epileptic process. Galanin exerts anticonvulsant effects through both type 1 and type 2 receptors, with distinct downstream signaling cascades. Several synthetic agonists of galanin receptors with optimized bioavailability have been synthesized and inhibited experimental seizures upon systemic administration, thus opening an opportunity for the development of galanin-based antiepileptic drugs.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18500639     DOI: 10.1007/s00018-008-8161-8

Source DB:  PubMed          Journal:  Cell Mol Life Sci        ISSN: 1420-682X            Impact factor:   9.261


  19 in total

1.  Generating orally active galanin analogues with analgesic activities.

Authors:  Charles R Robertson; Timothy H Pruess; Erin Grussendorf; H Steve White; Grzegorz Bulaj
Journal:  ChemMedChem       Date:  2012-02-28       Impact factor: 3.466

2.  Structural requirements for a lipoamino acid in modulating the anticonvulsant activities of systemically active galanin analogues.

Authors:  Liuyin Zhang; Charles R Robertson; Brad R Green; Timothy H Pruess; H Steve White; Grzegorz Bulaj
Journal:  J Med Chem       Date:  2009-03-12       Impact factor: 7.446

Review 3.  The role of the central noradrenergic system in behavioral inhibition.

Authors:  Eric A Stone; Yan Lin; Yasmeen Sarfraz; David Quartermain
Journal:  Brain Res Rev       Date:  2011-03-05

4.  Distinct gene expression profiles directed by the isoforms of the transcription factor neuron-restrictive silencer factor in human SK-N-AS neuroblastoma cells.

Authors:  Stuart G Gillies; Kate Haddley; Sylvia A Vasiliou; Gregory M Jacobson; Bengt von Mentzer; Vivien J Bubb; John P Quinn
Journal:  J Mol Neurosci       Date:  2010-07-23       Impact factor: 3.444

5.  Regulation of glucose and insulin release following acute and repeated treatment with the synthetic galanin analog NAX-5055.

Authors:  Sean P Flynn; H Steve White
Journal:  Neuropeptides       Date:  2015-01-21       Impact factor: 3.286

6.  Bidirectional regulation of stress responses by galanin in mice: involvement of galanin receptor subtype 1.

Authors:  K Mitsukawa; X Lu; T Bartfai
Journal:  Neuroscience       Date:  2009-03-09       Impact factor: 3.590

Review 7.  Effects of galanin on monoaminergic systems and HPA axis: Potential mechanisms underlying the effects of galanin on addiction- and stress-related behaviors.

Authors:  Marina R Picciotto; Christian Brabant; Emily B Einstein; Helen M Kamens; Nichole M Neugebauer
Journal:  Brain Res       Date:  2009-08-20       Impact factor: 3.252

Review 8.  Regulation of neurological and neuropsychiatric phenotypes by locus coeruleus-derived galanin.

Authors:  David Weinshenker; Philip V Holmes
Journal:  Brain Res       Date:  2015-11-20       Impact factor: 3.252

9.  Analyzing the validity of GalR1 and GalR2 antibodies using knockout mice.

Authors:  Xiaoying Lu; Tamas Bartfai
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2009-01-22       Impact factor: 3.000

10.  Developing novel antiepileptic drugs: characterization of NAX 5055, a systemically-active galanin analog, in epilepsy models.

Authors:  H Steve White; Erika A Scholl; Brian D Klein; Sean P Flynn; Timothy H Pruess; Brad R Green; Liuyin Zhang; Grzegorz Bulaj
Journal:  Neurotherapeutics       Date:  2009-04       Impact factor: 7.620

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.